#biotech

📰News 📈 Stocks

VHT vs. XBI: Comparing Broad Healthcare Exposure and Biotech Volatility

September 24, 2026 (47 days ago)

VHT and XBI offer distinct risk-reward profiles, with VHT providing diversified healthcare sector stability and XBI serving as a high-beta, concentrated play…

VHT XBI LLY +5

🌍 US Read More →

🔎Analyst 📈 Stocks

Goldman Sachs Initiates Tempus AI at Neutral With $75 Price Target

September 24, 2026 (47 days ago)

Goldman Sachs initiates Tempus AI at Neutral, balancing strong diagnostic growth and a $42 million Recursion partnership extension against looming contract renewal…

TEM RXRX

🌍 AMERICAS Read More →

📰News 📈 Stocks

Sandisk Surges 644% as AI Demand Drives Tech and Consumer Market Shifts

September 24, 2026 (47 days ago)

Sandisk rallies on AI demand while Meta's Muse release triggers a sell-off in travel and telecom stocks, and Immunovant halts a key…

IMVT SNDK META +3

🌍 AMERICAS Read More →

📰News 📈 Stocks

Biotech Sector Slumps 4% as RAPP, CLYM, and CGEM Lead Declines

September 23, 2026 (48 days ago)

Medical-Development Biotech stocks retreated 4% Wednesday, with Rapport Therapeutics, Climb Bio, and Cullinan Therapeutics leading the decline as the broader sector group…

RAPP CLYM CGEM

🌍 US Read More →

📰News 📈 Stocks

Jaguar Health Plunges 59% and Viking Therapeutics Slips 4% in Biotech Pullback

September 23, 2026 (48 days ago)

Biotech stocks Jaguar Health and Viking Therapeutics saw sharp declines on Wednesday, though both remain up significantly over the past month, suggesting…

JAGX VKTX

🌍 AMERICAS Read More →

📰News 📈 Stocks

CRISPR Therapeutics Trades 48% Below Consensus as CASGEVY Revenue Climbs

September 23, 2026 (48 days ago)

CRISPR Therapeutics remains a standout in the gene-editing sector as the only firm with an approved product, yet shares trade significantly below…

CRSP BEAM NTLA +3

🌍 AMERICAS Read More →

📊Earnings 📈 Stocks

Oxford Biomedica Revenue Rises 10% as Manufacturing Demand Strengthens

September 22, 2026 (49 days ago)

Oxford Biomedica posted improved H1 results with a 10% revenue gain and 22 new client signings, though management acknowledged minor program delays…

OXB

🌍 EUROPE Read More →

📊Earnings 📈 Stocks

PureTech Health Reports $220M Cash Runway Through 2028 in H1 Results

September 22, 2026 (49 days ago)

PureTech Health maintains a strong cash position through 2028 while advancing its portfolio via external financings for Seaport and Celea Therapeutics and…

PRTC BMY

🌍 AMERICAS Read More →

📰News 📈 Stocks

BioNTech Shares Slip as BMO Downgrades Stock Following Clinical Setback

September 22, 2026 (49 days ago)

BMO Capital Markets downgraded BioNTech to market perform, citing a failed Phase 2 clinical trial and lowered revenue guidance, though the company…

BNTX MRNA MRK

🌍 GLOBAL Read More →

🚀IPO 📈 Stocks

ADARx Targets $1.74 Billion Valuation in Upcoming Nasdaq IPO

September 21, 2026 (50 days ago)

ADARx Pharmaceuticals eyes a $1.74 billion valuation as it joins a wave of biotech listings, supported by a strategic $100 million investment…

ADRX ABBV Electra Therapeutics +1

🌍 US Read More →

📰News 📈 Stocks

Telix Pharmaceuticals Shares Slide Following $2.35 Billion ITM Merger Deal

September 21, 2026 (50 days ago)

Telix Pharmaceuticals stock drops as markets digest a $2.35 billion merger with Isotope Technologies Munich, overshadowing analyst optimism for the radiopharmaceutical firm.

TLX

🌍 GLOBAL Read More →

📰News 📈 Stocks

Cue Biopharma Shares Surge 41.6% on Positive Phase 2 Clinical Trial Results

September 21, 2026 (50 days ago)

Cue Biopharma stock jumped 41.6% as positive Phase 2 data for its urticaria treatment CUE-221 met key clinical endpoints, signaling a potential…

CUE

🌍 AMERICAS Read More →